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The cancer stem cell (CSC) hypothesis has sturdily re-emerged in
the last decade. Advocates of this model estimate that a signiﬁ-
cant number (if not all) of human cancers are developed and sus-
tained by a reduced number of cells with ‘‘stemness” properties
such as self-renewal, unlimited proliferative capacity, and asym-
metric division. Theoretically, tumor cells are organized accord-
ing to these properties, with CSCs located at the top of this
hierarchical pyramid [1]. There is also strong debate regarding
the origin of CSCs, existing data implicates de-differentiation,
arrest, and/or trans-differentiation in their generation. Robust
evidence supports the CSC model in some hematological malig-
nancies, whereas data in solid tumors are yet inconclusive.
Hepatocellular carcinoma (HCC) is an increasing health prob-
lem in United States and Europe, mainly due to the augmentation
of hepatitis C virus infection [2]. In fact, mortality has doubled
during the 1990–2005 interval in the USA [3]. Unlike most solid
tumors, it usually arises on a previously damaged organ. Liver cir-
rhosis of different etiologies (e.g., viral hepatitis, alcohol con-
sumption, NASH) is the precursor to HCC in more than 80% of
patients. In this context, inﬂammation and hepatocyte prolifera-
tion/regeneration are the pathological substrates that trigger
hepatocarcinogenesis, although additional factors such as certain
viral proteins (e.g., HCV core, HBX protein) may also contribute to
this process. Experimental data demonstrate activation and pro-
liferation of progenitor cells in cirrhotic livers, but their precise
oncogenic role remains controversial. In addition, cirrhosis favors
the development of dysplastic foci and nodules (i.e., preneoplas-
tic lesions for HCC onset [4]), although, little is known about the
molecular changes and cellular compartments (e.g., progenitor
cells, mature hepatocytes, cholangiocytes, etc.) implicated in
the cirrhosis-dysplasia-HCC transition.Journal of Hepatology 20
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E-mail address: augusto.villanueva@ciberehd.org (A. Villanueva).A recent study by Andersen et al. provides new insights into the
role of progenitor cells in HCC development, upon genomic analy-
sis of liver nodules in a ratmodel that recapitulates different stages
of human hepatocarcinogenesis [5]. The animal model entails two
chemical carcinogens and a partial hepatectomy that expand adult
stem cells and induce tumors, histologically resembling HCC. Rats
were euthanized at different time points (2.5, 9, and 14 months)
and the resulting hepatic nodules (i.e., focal lesions, adenomas,
early and advancedHCC)were classiﬁedaccording to their staining
status for glutathione S-transferase (i.e., amarker lost as stem cells
differentiate toward hepatocytes) and CK19 (i.e., a hepatic progen-
itor cell marker present also in adult biliary epithelium). In addi-
tion, nodules were microdissected and proﬁled using whole-
genomeexpressionmicroarrays.Authors foundadirect correlation
between CK19 staining and progressive stages of liver oncogenesis
in this model, being universal in HCC. Inverse correlation between
CK19 staining and markers of hepatocyte differentiation (e.g.,
HNF4) suggested that CK19+ lesions could retain a progenitor cell
origin. Interestingly, unsupervised clustering of gene expression
data identiﬁed two different groups of hepatic nodules, clusters
R1 and R2, which mimicked CK19 staining status. Subsequent
supervisedanalysis founddominanceofAP-1 signalingandenrich-
ment of the stem cell module map in CK19+ nodules, reinforcing
their progenitor origin. Predictions of this CK19 gene signature
were ﬁnally evaluated on 53 human HCCs, upon applying a com-
parative functional genomics approach [6]. Patients with this sig-
nature were enriched in the previously described progenitor-
type hepatoblast HCC [6] and had signiﬁcantly worse prognosis
on a univariate analysis.
This work complements previous genomic studies that identi-
ﬁed a subgroup of HCCs with a supposedly progenitor cell lineage
[6,7], and agree with the poor prognostic value conferred by pro-
genitor-derived signatures [8]. Rules of evidence and guidelines
for cancer biomarker studies still require further conﬁrmation of
the prognostic value of the CK19 signature for its ﬁnal incorpora-
tion in HCC clinical decision-making algorithms [9] (e.g., relation
of the signature to standard prognostic variables like vascular
invasion or presence of satellites, multivariate analysis, internal
and external validation, etc.). These guidelines (i.e., REMARK [9])
provide a useful road-map for evidence-based evaluation of
molecular prognostic markers in oncology. Interestingly, genomic
studies conducted in other solid tumors also suggest the prognos-
tic impact of signatures generated from a progenitor/stem cell
background (Table 1 [5–7,10–13]). Altogether, they prove the
existence of prognostic progenitor traits in solid tumors accessible
for genomic monitoring. Hypothetically, common biological
features contained in these proﬁles may code for a distinctive epi-10 vol. 53 j 578–579
Table 1. Relevant gene signatures with predicted progenitor/stem cell origin and pronostic impact in human cancer.
Cancer Gene signature Biological insights
Liver tumors
HCC CK19 signature [5] Up-regulation of AP-1 transcription factor (JUN/FOS pathway)
HCC EpCAM signature [7] Activation of Wnt/beta-catenin signaling pathway
HCC Hepatoblast signature_ClusterA [6] Enrichment of JUN and FOS pathway activity
Hepatoblastoma Hepatoblastoma_C2 class [11] Activation of Wnt/beta-catenin and Myc signaling pathway
Other tumors
Breast, lung, prostate, medulloblastoma Invasiveness gene signature [13] Activation of RAS and NFjB pathway
Multiple tumors MTTS/PNS signature [12] Activation of BMI-1 oncogene pathway
Breast, glioma, bladder Embryonic stem signature [10] Over-expression of Nanog, Oct4, Sox2, and c-Myc
JOURNAL OF HEPATOLOGYthelial progenitor/stem cell signature, potentially able to trace a
common ancestor of epithelial-derived malignancies.
Assumption of the CSC theory implies that liver cancer eradi-
cation will require drugs able to speciﬁcally target these cells, a
minor subpopulation within tumor bulk. Sorafenib, the sole
systemic agent approved for HCC treatment, probably exerts its
anti-tumoral properties by targeting cell proliferation and angio-
genesis. Due to the predicted low turnover of CSC, the challenge
is set to develop agents with a different mechanistic proﬁle (e.g.,
differentiation induction) and CSC-speciﬁc toxicity [14]. Animal
models such as the one used by Andersen et al. [5] would be rel-
evant to evaluate their anti-neoplastic performance in progeni-
tor-derived HCC. An ideal animal model, though, should also
recapitulate the underlying liver disease present in most HCC
patients (i.e., cirrhosis).Conﬂict of interests
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